Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent

Lee, Jung Hyun; Kang, Dae Hwan; Kim, Ji Young; Lee, Sun Mi; Kim, Do Hoon; Park, Chan Won; Cho, Hwal Suk; Kim, Gwang Ha; Kim, Tae Oh; Heo, Jeong; Song, Geun Am; Cho, Mong; Kim, Suk; Kim, Chang Won; Lee, Jun Woo

doi:10.1016/j.gie.2006.12.061

Cited by 94 publications

(90 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5 [SD]; after PTBD, 4.7 mg/dL Ϯ 4.2). Thirtysix patients were followed for at least 20 days after stent placement and six patients were lost to follow-up after 1 week.…”

Section: Clinical Resultsmentioning

confidence: 99%

“…Fluoroscopically and endoscopically guided T-or Y-configured stent placement have gained widespread acceptance as bilobar internal drainage methods (2)(3)(4)(5)(6). T-and Y-configured stent placement creates two intrahepatic limbs of the stent assembly to connect one right sectoral duct and the LHD.…”

Section: Discussionmentioning

confidence: 99%

“…PERCUTANEOUS palliation with metallic endoprostheses is the accepted method to relieve malignant biliary hilar obstruction (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11). Although the necessity of complete biliary drainage remains controversial, it seems certain that drainage of as much of the liver as possible is prudent (3)(4)(5)(6)(7)(8).…”

mentioning

confidence: 99%

“…Although the necessity of complete biliary drainage remains controversial, it seems certain that drainage of as much of the liver as possible is prudent (3)(4)(5)(6)(7)(8). Many reports regarding bilobar biliary stent implantation have been published (2)(3)(4)(5)(6). T-and Y-configured stent placement involves two intrahepatic limbs connecting one right-sector duct and the left hepatic duct (LHD) to the common bile duct (CBD).…”

mentioning

confidence: 99%

See 3 more Smart Citations

Crisscross-Configured Dual Stent Placement for Trisectoral Drainage in Patients with Advanced Biliary Hilar Malignancies

Bae

Park

Choi

et al. 2008

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

“…5 [SD]; after PTBD, 4.7 mg/dL Ϯ 4.2). Thirtysix patients were followed for at least 20 days after stent placement and six patients were lost to follow-up after 1 week.…”

Section: Clinical Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Crisscross-Configured Dual Stent Placement for Trisectoral Drainage in Patients with Advanced Biliary Hilar Malignancies

Bae

Park

Choi

et al. 2008

Journal of Vascular and Interventional Radiology

View full text Add to dashboard Cite

“…[1][2][3][4][5][6] Among them, PDT has been spotlighted as palliative therapy for the treatment of various types of cancer cells due to its composition of nontoxic components, such as photosensitizers, light, and oxygen, as well as its minimal side effects on patients. 1,6 Generally, a photosensitizer is activated only under light irradiation of a specific wavelength; ie, the photosensitizer alone is not harmful to the human body.…”

Section: Introductionmentioning

confidence: 99%

5-aminolevulinic acid-incorporated nanoparticles of methoxy poly(ethylene glycol)-chitosan copolymer for photodynamic therapy

Chung¹,

Chung²,

Jeong³

et al. 2013

IJN

Self Cite

View full text Add to dashboard Cite

Purpose: The aim of this study was to make 5-aminolevulinic acid (5-ALA)-incorporated nanoparticles using methoxy polyethylene glycol/chitosan (PEG-Chito) copolymer for application in photodynamic therapy for colon cancer cells. Methods: 5-ALA-incorporated (PEG-Chito-5-ALA) nanoparticles were prepared by ion complex formation between 5-ALA and chitosan. Protoporphyrin IX accumulation in the tumor cells and phototoxicity induced by PEG-Chito-5-ALA nanoparticles were assessed using CT26 cells in vitro.Results: PEG-Chito-5-ALA nanoparticles have spherical shapes with sizes diameters 200 nm. More specifically, microscopic observation revealed a core-shell structure of PEG-Chito-5-ALA nanoparticles.1 H NMR spectra showed that 5-ALA was incorporated in the core of the nanoparticles. In the absence of light irradiation, all components such as 5-ALA, empty nanoparticles, and PEG-Chito-5-ALA nanoparticles did not affect the viability of cells. However, 5-ALA or PEG-Chito-5-ALA nanoparticles induced tumor cell death under light irradiation, and the viability of tumor cells was dose-dependently decreased according to the increase in irradiation time. In particular, PEG-Chito-5-ALA nanoparticles induced increased phototoxicity and higher protoporphyrin IX accumulation into the tumor cells than did 5-ALA alone. Furthermore, PEG-Chito-5-ALA nanoparticles accelerated apoptosis/necrosis of tumor cells, compared to 5-ALA alone. Conclusion: PEG-Chito-5-ALA nanoparticles showed superior delivery capacity of 5-ALA and phototoxicity against tumor cells. These results show that PEG-Chito-5-ALA nanoparticles are promising candidates for photodynamic therapy of colon cancer cells.

show abstract

Risk factors for technical failure of endoscopic double self‐expandable metallic stent placement by partial stent‐in‐stent method

Kawakubo

Kawakami

Toyokawa

et al. 2014

J Hepato Biliary Pancreat

View full text Add to dashboard Cite

show abstract

Endoscopic bilateral metal stent placement for advanced hilar cholangiocarcinoma: a pilot study of a newly designed Y stent

Cited by 94 publications

References 15 publications

Crisscross-Configured Dual Stent Placement for Trisectoral Drainage in Patients with Advanced Biliary Hilar Malignancies

Crisscross-Configured Dual Stent Placement for Trisectoral Drainage in Patients with Advanced Biliary Hilar Malignancies

5-aminolevulinic acid-incorporated nanoparticles of methoxy poly(ethylene glycol)-chitosan copolymer for photodynamic therapy

Risk factors for technical failure of endoscopic double self‐expandable metallic stent placement by partial stent‐in‐stent method

Contact Info

Product

Resources

About